Objective: To compare efficacy and toxicity of 2 multiagent chemotherapeutic protocols similar in all respects except that 1 incorporated dactinomycin and the other incorporated doxorubicin for treatment of dogs with malignant lymphoma.
Design: Randomized controlled trial.
Animals: 45 dogs with malignant lymphoma.
Procedure: Dogs were randomly assigned to a doxorubicin or dactinomycin treatment group. Time to first remission, duration of first remission, survival time, and prevalence of toxicoses, particularly number of episodes of dose-limiting neutropenia and gastrointestinal toxicoses, were compared between groups.
Results: 37 dogs received at least 1 dose of doxorubicin (21 dogs) or dactinomycin (16). Median time to first remission was not significantly different between groups, but median duration of first remission and median survival time were significantly longer for dogs in the doxorubicin treatment group than for dogs in the dactinomycin treatment group. Number of dogs that died, number of episodes of dose-limiting neutropenia, and number of episodes of gastrointestinal toxicoses were not significantly different between groups.
Clinical Implications: A multiagent chemotherapeutic protocol incorporating doxorubicin was significantly more effective in dogs with malignant lymphoma than a similar protocol incorporating dactinomycin. Despite the lower cost and lack of cardiotoxicity, dactinomycin is not an equivalent substitute for doxorubicin in the initial treatment of dogs with malignant lymphoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Defects in the Mitochondrial Genome of Dogs with Recurrent Tumours.
Int J Mol Sci
December 2024
Institute of Biological Bases of Animal Production, University of Life Sciences in Lublin, Akademicka 13 St., 20-950 Lublin, Poland.
This study presents a comprehensive analysis of mitochondrial DNA (mtDNA) variations in dogs diagnosed with primary and recurrent tumours, employing Oxford Nanopore Technologies (ONT) for sequencing. Our investigation focused on mtDNA extracted from blood and tumour tissues of three dogs, aiming to pinpoint polymorphisms, mutations, and heteroplasmy levels that could influence mitochondrial function in cancer pathogenesis. Notably, we observed the presence of mutations in the D-loop region, especially in the VNTR region, which may be crucial for mitochondrial replication, transcription, and genome stability, suggesting its potential role in cancer progression.
View Article and Find Full Text PDFOxidative Status and Lipid Metabolism Analytes in Dogs with Mast Cell Tumors: A Preliminary Study.
Antioxidants (Basel)
November 2024
Diagnostic Laboratory, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 546 27 Thessaloniki, Greece.
Mast cell tumors (MCTs) are common skin neoplasms in dogs. Prognostic indicators include histologic grade, clinical stage, high Ki-67 index, elevated argyrophilic nucleolus organizer regions (AgNOR) index, mutations, and recurrence after surgery. Blood serum redox status has been shown to correlate with prognostic factors in canine lymphoma and mammary tumors.
View Article and Find Full Text PDFThe Immune Contexture in Canine Anal Sac Adenocarcinoma: Immunohistochemical Quantification of Tumor-Infiltrating Lymphocytes and Tumor-Associated Macrophages with Image Analysis.
Animals (Basel)
December 2024
Department of Veterinary Medical Sciences, University of Bologna, via Tolara di Sopra 50, 40064 Bologna, Italy.
Canine anal sac gland adenocarcinomas (ASACs) are locally aggressive and highly metastatic to regional lymph nodes. Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) can be effective prognostic and predictive markers in numerous human neoplasms and are increasingly investigated in dogs. The aim of this study was to characterize immune cells in canine ASACs and their relationship with tumor size, histologic metastatic status, and tumor clinical stage.
View Article and Find Full Text PDFRadical Mastectomy Efficiently Improves Long-Term Clinical Outcomes in Dogs with Malignant Mammary Tumors.
Animals (Basel)
December 2024
Department of Veterinary Surgery, College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Republic of Korea.
The incidence of mammary gland tumors in dogs is a significant issue, characterized by notable rates of malignancy, recurrence, and disease burden. However, the lack of comprehensive information and correlated studies has presented challenges in establishing an effective surgical treatment strategy. In this study, a cohort of 95 dogs diagnosed with mammary tumors underwent evaluation using various surgical methods, medications, ovariohysterectomy, and assessments of margin completeness to analyze clinical outcomes.
View Article and Find Full Text PDFComputed Tomography-Guided Radiofrequency Ablation of Nasal Carcinomas in Dogs.
Animals (Basel)
December 2024
VetCorner Unavets, 50012 Zaragoza, Spain.
Nasal carcinomas in dogs are locally invasive neoplasms with a low metastatic rate that pose significant treatment challenges due to their location and aggressiveness. This study evaluates the safety, feasibility, and therapeutic outcomes of computed tomography-guided radiofrequency ablation (CT-guided RFA) in 15 dogs diagnosed with nasal adenocarcinoma. All patients underwent staging and histopathological diagnosis before treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!